Predictive biomarkers of response for immune checkpoint inhibitors in non–small-cell lung cancer

Arsela Prelaj; Rebecca Tay; Roberto Ferrara; Nathalie Chaput; Benjamin Besse; Raffaele Califano

doi:10.1016/j.ejca.2018.11.002

Predictive biomarkers of response for immune checkpoint inhibitors in non–small-cell lung cancer

Arsela Prelaj, Rebecca Tay, Roberto Ferrara, Nathalie Chaput, Benjamin Besse, Raffaele Califano

Résultats de recherche: Contribution à un journal › Article 'review' › Revue par des pairs

162 Citations (Scopus)

Résumé

Immune checkpoint blockade has been a pivotal development in the management of advanced non–small-cell lung cancer (NSCLC). Although durable antitumour activity and improved survival have been observed in a subset of patients, there is a need for additional predictive biomarkers to improve patient selection and avoid toxicity in potential non-responders. This review will address the use and limitations of tumour programmed death-ligand 1 expression as a predictive biomarker and review emerging biomarker strategies specifically related to NSCLC including genetic alterations (tumour mutation burden, loss and gain activated mutations), tumour-related factors (tumour microenvironment) and factors related to the host immune system. Novel approaches in biomarker detection such as peripheral blood monitoring will also be reviewed.

langue originale	Anglais
Pages (de - à)	144-159
Nombre de pages	16
journal	European Journal of Cancer
Volume	106
Les DOIs	https://doi.org/10.1016/j.ejca.2018.11.002
état	Publié - 1 janv. 2019

Accès au document

10.1016/j.ejca.2018.11.002

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{050d0830b28f42d9a89c1a8ffbc468d1,

title = "Predictive biomarkers of response for immune checkpoint inhibitors in non–small-cell lung cancer",

abstract = "Immune checkpoint blockade has been a pivotal development in the management of advanced non–small-cell lung cancer (NSCLC). Although durable antitumour activity and improved survival have been observed in a subset of patients, there is a need for additional predictive biomarkers to improve patient selection and avoid toxicity in potential non-responders. This review will address the use and limitations of tumour programmed death-ligand 1 expression as a predictive biomarker and review emerging biomarker strategies specifically related to NSCLC including genetic alterations (tumour mutation burden, loss and gain activated mutations), tumour-related factors (tumour microenvironment) and factors related to the host immune system. Novel approaches in biomarker detection such as peripheral blood monitoring will also be reviewed.",

keywords = "Immunotherapy, Lung cancer, Microsatellite instability, NSCLC, PD-L1, Predictive biomarkers, Tumour microenvironment, Tumour mutational burden",

author = "Arsela Prelaj and Rebecca Tay and Roberto Ferrara and Nathalie Chaput and Benjamin Besse and Raffaele Califano",

note = "Publisher Copyright: {\textcopyright} 2018 Elsevier Ltd",

year = "2019",

month = jan,

day = "1",

doi = "10.1016/j.ejca.2018.11.002",

language = "English",

volume = "106",

pages = "144--159",

journal = "European Journal of Cancer",

issn = "0959-8049",

}

TY - JOUR

T1 - Predictive biomarkers of response for immune checkpoint inhibitors in non–small-cell lung cancer

AU - Prelaj, Arsela

AU - Tay, Rebecca

AU - Ferrara, Roberto

AU - Chaput, Nathalie

AU - Besse, Benjamin

AU - Califano, Raffaele

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Immune checkpoint blockade has been a pivotal development in the management of advanced non–small-cell lung cancer (NSCLC). Although durable antitumour activity and improved survival have been observed in a subset of patients, there is a need for additional predictive biomarkers to improve patient selection and avoid toxicity in potential non-responders. This review will address the use and limitations of tumour programmed death-ligand 1 expression as a predictive biomarker and review emerging biomarker strategies specifically related to NSCLC including genetic alterations (tumour mutation burden, loss and gain activated mutations), tumour-related factors (tumour microenvironment) and factors related to the host immune system. Novel approaches in biomarker detection such as peripheral blood monitoring will also be reviewed.

AB - Immune checkpoint blockade has been a pivotal development in the management of advanced non–small-cell lung cancer (NSCLC). Although durable antitumour activity and improved survival have been observed in a subset of patients, there is a need for additional predictive biomarkers to improve patient selection and avoid toxicity in potential non-responders. This review will address the use and limitations of tumour programmed death-ligand 1 expression as a predictive biomarker and review emerging biomarker strategies specifically related to NSCLC including genetic alterations (tumour mutation burden, loss and gain activated mutations), tumour-related factors (tumour microenvironment) and factors related to the host immune system. Novel approaches in biomarker detection such as peripheral blood monitoring will also be reviewed.

KW - Immunotherapy

KW - Lung cancer

KW - Microsatellite instability

KW - NSCLC

KW - PD-L1

KW - Predictive biomarkers

KW - Tumour microenvironment

KW - Tumour mutational burden

UR - http://www.scopus.com/inward/record.url?scp=85057838276&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2018.11.002

DO - 10.1016/j.ejca.2018.11.002

M3 - Review article

C2 - 30528799

AN - SCOPUS:85057838276

SN - 0959-8049

VL - 106

SP - 144

EP - 159

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -